Epygenix Therapeutics, Inc. Email Format
Biotechnology ResearchNew Jersey, United States2-10 Employees
In 2024, Epygenix emerged in the news regarding the initiation of a second phase 3 study in children with Lennox-Gastaut syndrome, highlighting ongoing late-stage development within its epilepsy program. The firm has been positioned within the broader CNS and rare epilepsy landscape, seeking to expand its pipeline through rigorous clinical evaluation. This context places Epygenix within the specialty biopharma segment dedicated to high-need neurological conditions, operating under a focused, research-driven mandate.